Prostate cancer death is unlikely in high‐risk patients following quality permanent interstitial brachytherapy
Open Access
- 12 August 2010
- journal article
- Published by Wiley in BJU International
- Vol. 107 (2), 226-232
- https://doi.org/10.1111/j.1464-410x.2010.09486.x
Abstract
Study Type – Therapy (case series)Level of Evidence 4 What’s known on the subject? and What does the study add? The management of high‐risk prostate cancer remains controversial. These patients remain at substantial risk for prostate cancer failure and death despite potentially curative therapy. In recent years, high quality brachytherapy with or without supplemental therapies to consist of moderate dose external beam radiation therapy and androgen deprivation therapy has resulted in marked improvement in biochemical control and a decrease in prostate cancer deaths. With aggressive high quality brachytherapy, the risk of death from diseases of the heart is twice as great as that of prostate cancer. OBJECTIVE To evaluate cause‐specific survival (CSS), biochemical progression‐free survival (bPFS) and overall survival (OS) in high‐risk prostate cancer brachytherapy patients. PATIENTS AND METHODS From April 1995 to June 2005, 284 patients with high‐risk prostate cancer (Gleason score ≥8 or prostate‐specific antigen >20 ng/mL or clinical stage ≥ T2c) underwent brachytherapy. Supplemental external beam radiation therapy was given to 257 (90.5%) patients and 179 (63.0%) received androgen deprivation therapy (ADT). Median follow up was 7.8 years. The median post‐implant day 0 D90 was 118.9% of prescription dose. Patients with metastatic prostate cancer or castrate‐resistant disease without obvious metastases who died of any cause were classified as dead from prostate cancer. Multiple parameters were evaluated for impact on survival. RESULTS Twelve‐year CSS, bPFS and OS were 94.2%, 89.0% and 69.7%. On multivariate analysis, bPFS was best predicted by percent positive biopsies and ADT. The analysis failed to identify any predictors for CSS, while OS was highly correlated with patient age, percent positive biopsies and diabetes. Fourteen percent of patients died from diseases of the heart, while 8%, 8% and 6% of patients died from non‐prostate cancer, other causes and prostate cancer, respectively. When OS was stratified by patients with 0–3 vs ≥4 comorbidities, the 12‐year OS was 73.0% and 52.7% (P= 0.036). CONCLUSIONS High‐quality brachytherapy results in favourable bPFS and CSS for high‐risk patients. Death from diseases of the heart is more than twice as likely as death from prostate cancer. Strategies to improve cardiovascular health may positively impact OS.Keywords
This publication has 32 references indexed in Scilit:
- Prostate cancer death is unlikely in high‐risk patients following quality permanent interstitial brachytherapyBJU International, 2010
- Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapyBJU International, 2009
- Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen EraJournal of Clinical Oncology, 2009
- Predictive models in external beam radiotherapy for clinically localized prostate cancerCancer, 2009
- Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical TrialJournal of Urology, 2009
- The Specific Definition of High Risk Prostate Cancer Has Minimal Impact on Biochemical Relapse-Free SurvivalJournal of Urology, 2009
- Androgen Deprivation Therapy Does Not Impact Cause-Specific or Overall Survival in High-Risk Prostate Cancer Managed With Brachytherapy and Supplemental External BeamInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Defining High Risk Prostate Cancer With Risk Groups and Nomograms: Implications for Designing Clinical TrialsJournal of Urology, 2006
- Treatment Margins Predict Biochemical Outcomes After Prostate BrachytherapyThe Cancer Journal, 2004